Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

3S Pharmaceutical Group China

3SBio is a fully-integrated biotechnology company in China with commercial and R&D programs in oncology, auto-immune diseases, nephrology, metabolic diseases and dermatology, and seeking in-licensing opportunity of novel therapies and technologies.

3SBio is actively pursuing international expansion through acquisitions, licensing and strategic partnerships. Please visit www.3sbio.com for more information.

We look forward to having opportunity to discuss potential collaboration with you.

Website:
www.3sbio.com
Company Size (Fulltime employees)
5000+
Year of foundation
1993
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
Zhao Peng
Senior BD Manager 

Achelios Therapeutics United States

Achelios Therapeutics, Inc., based in RTP Carolina, is a privately held specialty biopharmaceutical company whose core competency is the reformulation of non-steroidal anti-inflammatory drug (NSAID) molecules that have historically been used to treat pain and inflammation by topical application.
Our proprietary formulation allows for fast and enhanced delivery of active agents across human skin into subdermal tissues.
Achelios is currently developing:
OTC 1% diclofenac topical formulation for the treatment of pain and inflammation. Our product shows improved efficacy, better compliance, photoprotection, and dossing schedule vs. Voltaren® ANDA to be submitted in 4Q 2021.
The next product in development is a superior 3% diclofenac formulation being developed for the prescription market for acute and chronic pain. These product has demonstrated greater efficacy, safety and photostability vs. other topical gels available globally. Our product has also shown efficacy as an opioid-spearing agent in the treatment of pain.
Website:
Achelios.com
Company Size (Fulltime employees)
1-10
Year of foundation
2012
Partnering Objectives
Please specify your partnering goal
1. License OTC and RX product ex -US , Asia and EU
Headquartner in China
No
Biotech/Pharma Category
Assets Information 1
OTC1% diclofenac|Topical NSAID|pain and inflamation|global
Assets Information 2
Prescription 3% Diclofenac|Topical NSAID|Acute and chronic pain, opioid spearing|global
Assets Information 3
5%& 3% Ketoprofen topical|Topical Ketoprofen gel|Migraine, TMJD , Chronic pain|global
Biotech/Pharma Asset Stage
Dr. Crist Frangakis
President & ceo 
Functionality
Management

Acon Pharmaceuticals Inc United States

ACON Pharmaceuticals Inc. (ACON Pharma) is a specialty pharmaceutical company and focuses on siRNA and mRNA nanoparticle delivery, 505(b)(2) NDA, and complex ANDA drug product development with its captive drug delivery system and technology platforms. Acon Pharma is a privately held corporation located in Princeton, New Jersey, USA. As a dynamic pharmaceutical company in a vibrant life science research region, Acon Pharma leverages the expertise and experience of highly skilled, multi-disciplinary workforce to accelerate the product development of complex drug delivery systems. The Company’s key managers were primarily educated in US with advanced degrees and trained in the pharmaceutical industry for many years, and have possessed deep professional knowledge, technical know-how, and extensive experiences in pharmaceutical product development.

We are currently raising 5 million dollar fund to support IND-enabling studies for our patented liposomal siRNA for treatment of pulmonary fibrosis and long-acting microsphere for treatment of schizophrenia. We are also developing delayed release nanoemulsion for osteoporosis, and sustained release gel for fungal infection.
Website:
www.aconpharma.com
Company Size (Fulltime employees)
1-10
Year of foundation
2020
Partnering Objectives
Please specify your partnering goal
Looking for investors and strategic partners
Headquartner in China
No
Biotech/Pharma Category
Assets Information 1
AP1302|siRNA Liposome Inhalation|pulmonary fibrosis|China, US
Assets Information 2
AP2602|Long-acting Microsphere Injection|schizophrenia, bipolar disease|China, US
Assets Information 3
AP6111|Self-emulsifying Nanoemulsion|osteoporosis|China, US
Biotech/Pharma Asset Stage
Xudong Yuan
CEO 
Functionality
Management

Adragos Pharma Germany

Private equity firm
Website:
https://www.adragos-pharma.com/
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
Both raising further funds and driving deal pipeline
Headquartner in China
No
Biotech/Pharma Category
Mr. Andreas Raabe
Partner 
Functionality
Management

Aeola Health Solutions United States

An investment group transforming

the world of healthcare one sector at a time.

We consolidate CROs and medical labs.
Website:
aeolahealthsolutions.com
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
Find potential investors and strategic partners. Our strategy allows investors to triple their investment.
Headquartner in China
No
Biotech/Pharma Category
Mr. Michael Ezem
Aeola Health Solutions 
Functionality
Investment

Avancpharma China

Manufacturing company
Website:
www.avancpharma.com
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
Hayden Gu
BD 

Bayer China

Pharma
Website:
Www.bayer.com
Partnering Objectives
Headquartner in China
No
Biotech/Pharma Category
Cheryl Yang
BD AD 

Bayer Healthcare China

Bayer Healthcare
Website:
bayer.com
Company Size (Fulltime employees)
5000+
Partnering Objectives
Please specify your partnering goal
Looking for potential collaboration and/or investment opportunities for technology platforms in innovation therapeutics
Headquartner in China
No
Biotech/Pharma Category
Dr. Min Pang
Alliance Manager 
Functionality
Preclinical External Innovation

Capital Family Office United States

Investor
Website:
na
Company Size (Fulltime employees)
1-10
Year of foundation
2016
Partnering Objectives
Please specify your partnering goal
JV's; Licensing in/out
Headquartner in China
No
Biotech/Pharma Category
Steven Olasky
Pricipal 
Functionality
Investment

Covate Pharma Singapore

Based Singapore, to partner drug development for US/EU/ASEAN market. Founder background - Pharmacist background with PHD, School of Pharmacy London, UK - Worked in Early drug discover and development @ Novartis-UK , commercial side Manufacturing science and technology MS&T in Novartis - Singapore and - Global technical operations -GTO, MSD - Singapore; Drug Device combination products. - Involved in successful filing of several INDs applied the concepts to drug development in a virtual small Biotech, to prepare for Phase 3 clinical trials Partnering objectives - Partner with likeminded companies to address the challenges posed by Covid-19 pandemic - Entrepreneurship, Start-ups, Joint ventures, Fundraising Primary area of expertise Drug Development, IND, NDA, Process validation, CMC, Technology transfer, Digital medicines, Digital Therapies, Entrepreneurship

Website:
in progress
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
Drug development
Headquartner in China
No
Biotech/Pharma Category
Slides Deck
(pdf, 493.71KB)
Dr. Ameet Ambarkhane
Director